Search
Cerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigational[L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency. … [A264354, A264369] As a recombinant human TPP1, cerliponase alfa is used as an enzyme replacement therapy to restore the levels of TPP1 in patients with CLN2.[L51339]
Rilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigationalRilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune … Rilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies.
Synonyms: (e/z)-(r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrileDiosmin
go.drugbank.com/drugs/DB08995ApprovedInvestigationalChronic venous insufficiency is a common condition the western population. … Diosmin is widely available over-the-counter and demonstrates a favourable a favorable safety profile.[A232890,T840,L33040]
Ropinirole
go.drugbank.com/drugs/DB00268ApprovedInvestigationalIn 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. … Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease.
Triheptanoin
go.drugbank.com/drugs/DB11677ApprovedInvestigationalTriheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. … [A214812,A214817] Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin.
Selumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigational[A193608] It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications, including the development of multiple tumours in the nervous system … Most recently, on November 20, 2025, the FDA expanded this indication to include adults [L53881]
Bamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigational[L15316, L15321] Under the EUA granted in February 2021, bamlanivimab is used in combination with [etesevimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk … [A224044, L20974] It is set to enter phase 3 clinical trials.
Hyaluronidase (human recombinant)
go.drugbank.com/drugs/DB06205ApprovedInvestigational[A199026] Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics. … [A4033] Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.
Ocrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigational[A31739] Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS … It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada.
Acalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigationalexpected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK. … the therapeutic uses of acalabrutinib [L1009].